Featured Research

from universities, journals, and other organizations

Raloxifene After Tamoxifen Not Beneficial, According To New Study

Date:
February 20, 2002
Source:
Northwestern University
Summary:
Taking raloxifene after five years of tamoxifen therapy does not prevent the recurrence of breast cancer in postmenopausal women and may actually stimulate growth of endometrial tumors, according to a Northwestern University study.

Taking raloxifene after five years of tamoxifen therapy does not prevent the recurrence of breast cancer in postmenopausal women and may actually stimulate growth of endometrial tumors, according to a Northwestern University study.

Related Articles


As described in an article in the Feb. 20 issue of the Journal of the National Cancer Institute, researchers Ruth M. O’Regan, M.D.,V. Craig Jordan and colleagues at Northwestern evaluated the effects on tumor growth of raloxifene after tamoxifen treatment in mouse models of breast and endometrial cancers.

They found that, after exposing breast and endometrial tumors in mice to combinations of estrogen, tamoxifen, raloxifene or no drug at all, raloxifene did not further prevent growth of breast tumors previously exposed to more than five years of tamoxifen. Moreover, raloxifene was less effective than tamoxifen in blocking the growth of endometrial tumors caused by low-dose estrogen.

Tamoxifen is a selective estrogen receptor modulator (SERM) that reduces breast cancer recurrence in women with early-stage breast cancer. However, studies show that the benefits of tamoxifen diminish after five years and that additional therapy with tamoxifen may significantly increase a woman’s risk for endometrial cancer.

Some studies have suggested that SERM raloxifene, which is used to prevent osteoporosis in postmenopausal women, may decrease risk for breast cancer without increasing risk for endometrial cancer.

Based on the results of their study, the Northwestern researchers now believe that in women completing five years of tamoxifen therapy, raloxifene may not further reduce the risk for breast cancer recurrence.

However, the ongoing Study of Tamoxifen and Raloxifene (STAR) study, a large randomized clinical trial that is comparing the effects of raloxifene and tamoxifen on the primary prevention of breast cancer and endometrial cancer in high-risk women, may provide more definitive answers on the utility of raloxifene following tamoxifen therapy.

O’Regan is an instructor in medicine at Northwestern University Medical School. Jordan is the Diana, Princess of Wales, Professor of Cancer Research; professor molecular pharmacology and biological chemistry at the Medical School; and director of Lynn Sage Breast Cancer Research Program at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Co-authors on the article include Cancer Center researchers Csaba Gajdos, Alex De Los Reyes, Woochan Park and Alfred W. Rademaker. Rita C. Dardes is affiliated with the Federal University of Sao Paulo, Brazil.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "Raloxifene After Tamoxifen Not Beneficial, According To New Study." ScienceDaily. ScienceDaily, 20 February 2002. <www.sciencedaily.com/releases/2002/02/020220075200.htm>.
Northwestern University. (2002, February 20). Raloxifene After Tamoxifen Not Beneficial, According To New Study. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2002/02/020220075200.htm
Northwestern University. "Raloxifene After Tamoxifen Not Beneficial, According To New Study." ScienceDaily. www.sciencedaily.com/releases/2002/02/020220075200.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins